BeiGene announced its financial results, showing a total global revenue of $1.7 billion in the second quarter, a 30% year-over-year increase, and a GAAP net profit of $237 million, up 151% year-over-year. Driven by this performance growth, the company simultaneously raised its full-year 2026 total revenue guidance to $6.6 billion to $6.8 billion, higher than previous expectations. Global sales of its core product, zanubrutinib, reached $1.2 billion, a 31% year-over-year increase. The company also announced an additional $300 million investment to expand its manufacturing and R&D center in New Jersey, USA, and received accelerated approval from the U.S. FDA for tislelizumab for adult patients with relapsed/refractory mantle cell lymphoma.